We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+11.17%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$469M
AUM Growth
+$65.3M
Cap. Flow
+$30.3M
Cap. Flow %
6.45%
Top 10 Hldgs %
67.79%
Holding
39
New
8
Increased
4
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$27.4M
2
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$24.2M
3
CBIO
Crescent Biopharma
CBIO
+$16.9M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$8.47M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$6.24M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$19.2M
2
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$11.4M
3
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$8.82M
4
QLTI
QLT Inc
QLTI
+$5.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$2.05M

Sector Composition

Rank Sector Weight
1 Healthcare 70.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.64M 0.56%
22,920
– –
OREX
27
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.26M 0.48%
+525,210
New +$2.37M
SVRA icon
28
Savara
SVRA
$1.11B
$1.74M 0.37%
52,814
– –
GYRE icon
29
Gyre Therapeutics
GYRE
$635M
$1.48M 0.31%
8,631
– –
GBIM
30
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
$1.28M 0.27%
657,653
– –
CALA
31
DELISTED
Calithera Biosciences, Inc
CALA
$450K 0.1%
6,070
-2,075
-25% -$208K
PVLA
32
Palvella Therapeutics
PVLA
$2.03B
$389K 0.08%
+3,017
New +$462K
VXRT
33
DELISTED
Vaxart
VXRT
$292K 0.06%
18,941
-12,948
-41% -$215K
IRWD icon
34
Ironwood Pharmaceuticals
IRWD
$688M
– –
-2,096,360
Closed -$19.2M
LOXO
35
DELISTED
Loxo Oncology, Inc
LOXO
– –
-74,870
Closed -$2.05M
RXDX
36
DELISTED
Ignyta, Inc.
RXDX
– –
-50,000
Closed -$339K
CPXX
37
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-800,000
Closed -$8.82M
NRX
38
DELISTED
NEPHROGENEX INC COM
NRX
– –
-392,156
Closed -$184K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2016 Portfolio in Review

As of Q2 2016, BVF Inc held 39 positions worth $469M, up 16% from $404M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

BVF Inc deployed $30.3M of net new capital in Q2 2016, opening 8 new positions and adding to 4 existing holdings. Its largest new stake was Ionis Pharmaceuticals: 850,000 shares worth $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 64% a quarter earlier.

On the sell side, the largest reduction was VITAE PHARMACEUTICALS INC COMMON STOCK, an estimated $11.4M trimmed.

  • BVF Inc's largest Q2 2016 buy was Ionis Pharmaceuticals: 850,000 shares worth $19.8M.
  • BVF Inc added most to Cytokinetics in Q2 2016, an estimated $5.32M increase.
  • BVF Inc's biggest Q2 2016 reduction was VITAE PHARMACEUTICALS INC COMMON STOCK, cutting an estimated $11.4M.
  • BVF Inc fully exited Ironwood Pharmaceuticals in Q2 2016, selling an estimated $19.2M.
  • BVF Inc's ten largest holdings make up 68% of its $469M portfolio in Q2 2016.
  • BVF Inc opened 8 new positions and closed 5 in Q2 2016.
  • BVF Inc's portfolio value rose 16% quarter-over-quarter to $469M.

Based on BVF Inc's 13F filing for Q2 2016, filed 15 Aug 2016.